In September 2018, the Centers for Medicare & Medicaid Services (CMS) sent an email announcing that it would no longer cover Auryxia®. Auryxia® is an FDA approved medicine that treats iron deficiency ...

We issued an updated research report on Keryx Biopharmaceuticals, Inc. KERX on Sep 26, 2017. Notably, the company’s only marketed product, Auryxia (ferric citrate) is approved in the United States for ...

At any point during the 16-week efficacy period, 52.1% (n=61/117) of the Auryxia treated group demonstrated hemoglobin levels of ≥1g/dL compared to 19.1% (n=22/115) of the placebo group. The Food and ...

Keryx’s Auryxia has so far struggled to get off the ground. But after winning its second FDA approval, the company’s now prepping for a launch that it thinks can take the drug to the next level.

(RTTNews) - Akebia Therapeutics, Inc. (AKBA) Thursday announced positive results from its Phase 4 collaborative study, IMPACT, which examined the effects of Auryxia or ferric citrate as the primary ...

Akebia Therapeutics, a small Cambridge, Mass.-based drugmaker, has filed a lawsuit against CMS, claiming Medicare’s denial to cover its anemia drug violates the law, according to STAT. Akebia’s only ...

Keryx Biopharmaceuticals Inc.’s KERX shares rallied 3.8% on the company’s announcement of additional data from a phase III study on Auryxia for the treatment of iron deficiency anemia (IDA) in ...

Keryx Biopharmaceuticals announced an interruption will occur in the supply of Auryxia (ferric citrate) tablets due to a production-related issue. Keryx Biopharmaceuticals announced an interruption ...

Akebia Therapeutics' stock is down 28% after a proposed stock offering, with declining Auryxia revenues and significant financial challenges. Vafseo's market launch shows some promise, but it's a ...

DUBLIN--(BUSINESS WIRE)--The "Drug Analysis: Auryxia" drug pipelines has been added to ResearchAndMarkets.com's offering. Auryxia (ferric citrate; Keryx Biopharmaceuticals/Japan Tobacco/Torii ...

Akebia Therapeutics (NASDAQ:AKBA) stock fell ~22% on Thursday despite Q4 results beating estimates. Net loss narrowed to -$7.55M, compared to -$70.68M in Q4 2021. Total revenue declined -7.4% Y/Y to ...